Skip to content
BHP

Peptides studied for burn healing research

Last reviewed:

Burn healing research peptides target re-epithelialisation rate, microvascular regeneration, and scar quality — with GHK-Cu and LL-37 contributing antimicrobial and pro-regenerative effects relevant to partial-thickness burns.

GHK-Cu reduced TGF-β1 expression in burn wound models, raising research interest in its potential to limit hypertrophic scar formation — one of the most significant long-term quality-of-life burdens after partial-thickness burns.

— Notable finding

Condition background

Thermal burns affect approximately 250,000 people per year in the UK who require medical attention, with around 175,000 presenting to emergency departments. Burns are classified by depth: superficial (epidermal only), partial-thickness (superficial or deep dermal), and full-thickness. Partial-thickness burns — particularly deep-dermal — represent the most clinically challenging healing context, as spontaneous re-epithelialisation is slow and incomplete, infection risk is high, and hypertrophic scarring is common. Full-thickness burns require surgical debridement and skin grafting. The pathophysiology of burn wound healing involves an acute hyperinflammatory response at the wound periphery (the 'zone of stasis'), systemic inflammatory activation with cytokine storm in major burns, impaired keratinocyte migration due to altered matrix composition, and dysregulation of the collagen remodelling process that determines scar outcome. Burn-wound infection — particularly with Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA) — is a leading cause of deepening wound conversion and mortality in extensive burns.

Current treatment landscape

UK burn management is provided in specialist burn units following NICE guidance (NG32) and National Burn Care Standards. Initial management follows the ATLS and EMSB algorithms: airway protection, fluid resuscitation (Parkland or Muir-Barclay formulae), analgesia, and wound cooling. Wound dressings for partial-thickness burns include silver-impregnated materials (Mepilex Ag, Aquacel Ag), biologically active dressings (Biobrane, TransCyte), and negative-pressure wound therapy for specific indications. Surgical management of deep-dermal and full-thickness burns involves early tangential excision and split-thickness skin grafting. Cultured epithelial autografts (CEA) and dermal substitutes (Integra, Matriderm) are used where donor-site availability is limited. Scar management — compression therapy, silicone products, laser, and surgical revision — begins during the remodelling phase. Despite advances, hypertrophic scarring remains a significant quality-of-life burden.

Why peptides are studied here

Burn healing research peptides are principally studied for three goals: accelerating re-epithelialisation, reducing infection risk, and improving scar quality. [GHK-Cu](/peptides/ghk-cu) promotes keratinocyte and fibroblast migration, stimulates VEGF for angiogenesis in the regenerating dermis, upregulates anti-oxidant gene expression (superoxide dismutase, catalase) that may limit oxidative damage in the zone of stasis, and modulates collagen type I/III balance during remodelling — a key determinant of scar texture and pliability. [LL-37](/peptides/ll-37) has direct broad-spectrum antimicrobial activity relevant to burn-wound infection prevention, alongside keratinocyte migration stimulation and angiogenesis promotion via FPR2 and VEGF pathways. Its endogenous deficiency in burned tissue (cathelicidin production is suppressed in severe burn patients) provides a mechanistic rationale for supplementation research. [Thymosin beta-4](/peptides/thymosin-beta-4) has demonstrated keratinocyte and endothelial cell migration promotion in corneal and skin wound models through actin polymerisation and VEGF upregulation. [BPC-157](/peptides/bpc-157) contributes angiogenic and NO-system-mediated vascular repair relevant to the ischaemic zone of stasis.

Relevant research peptides

Notable study findings

  • GHK-Cu

    GHK-Cu applied to partial-thickness burn wounds in rodent models accelerated re-epithelialisation, increased angiogenesis density in the healing dermis, and reduced TGF-β1 expression — a finding relevant to hypertrophic scar prevention, as TGF-β1 is a primary driver of excessive collagen deposition.

  • LL-37

    Exogenous LL-37 application reduced Pseudomonas aeruginosa colonisation and MRSA burden in burn wound models while simultaneously promoting keratinocyte migration and wound closure — demonstrating the dual antimicrobial and pro-regenerative profile relevant to infected burns.

  • Thymosin beta-4

    Thymosin beta-4 accelerated corneal re-epithelialisation and skin wound closure in multiple published models through actin polymerisation-driven keratinocyte migration, with concurrent VEGF upregulation supporting the vascular component of wound repair.

Relevant research stacks

UK regulatory notes

GHK-Cu, LL-37, thymosin beta-4, and BPC-157 are not MHRA-licensed for burn wound management or any other human indication in the UK. BPC-157 is listed on the WADA Prohibited List under S0. LL-37, GHK-Cu, and thymosin beta-4 are not currently WADA-listed. Given that burn injuries occur predominantly in civilian non-athletic populations, WADA status is less commonly relevant here, but researchers should verify annually. All content is for laboratory research reference only.

Frequently asked questions

What is the zone of stasis and why is it clinically important?
The zone of stasis is the intermediate layer of a burn wound surrounding the central coagulation necrosis zone. Tissue in the zone of stasis is initially viable but at risk of progression to necrosis due to microvascular occlusion, oedema, and oxidative stress. If perfusion is restored and inflammation is limited in the first 24–72 hours, the zone of stasis may survive; if not, it undergoes conversion to full-thickness necrosis, deepening the burn and increasing the area requiring grafting. Protecting the zone of stasis is a key early management goal.
Why is infection such a significant concern in burn wounds?
Burns destroy the skin's physical and immunological barrier function. The burn eschar provides a rich protein medium for bacterial growth, while local and systemic immune dysfunction — including reduced neutrophil function and cathelicidin production — impairs the patient's ability to clear pathogenic organisms. Pseudomonas aeruginosa and MRSA are particularly problematic as they form biofilms resistant to standard antibiotics and can convert a partial-thickness wound to full-thickness by bacterial proteolytic activity.
How does LL-37 deficiency develop in burn patients?
In severe burns, systemic inflammatory activation leads to a paradoxical immune suppression phase — including reduced production of antimicrobial peptides such as LL-37 by keratinocytes and neutrophils. Additionally, the wound environment itself — high protease activity and altered pH — degrades endogenous antimicrobial peptides more rapidly. This acquired cathelicidin deficiency has been proposed as a mechanistic contributor to the high infection susceptibility of burn patients.
What is hypertrophic scarring and which peptide mechanisms might reduce it?
Hypertrophic scarring occurs when collagen production during the remodelling phase exceeds collagen degradation, producing an elevated, rigid scar with impaired pliability and cosmetic outcome. TGF-β1 is the principal driver of pathological fibroblast activation and collagen overproduction. GHK-Cu's capacity to reduce TGF-β1 expression and modulate MMP-mediated collagen turnover makes it a mechanistically interesting research candidate for scar quality improvement.
Is thymosin beta-4 studied in skin specifically or only in corneal models?
Thymosin beta-4 was first studied in corneal wound healing, where early published data (Sosne et al.) showed accelerated re-epithelialisation in murine corneal models. Subsequent research has extended findings to full-thickness skin excisional models, myocardial infarction, and tendon injury. The underlying mechanism — promotion of actin polymerisation driving cell migration — is not tissue-specific, providing a plausible basis for its relevance to skin burn research.
What endpoints are used in burn healing peptide research?
Standard pre-clinical endpoints include wound surface area measurement over time (digital planimetry), histological assessment of epidermal thickness and dermal vascularity, immunohistochemical staining for Ki-67 (proliferation), cytokeratin-14 (keratinocyte maturation), CD31 (vessel density), collagen type I/III ratio, and TGF-β1 and MMP expression. In infection models, bacterial colony counts are added as a primary endpoint.

Where to source research peptides for laboratory research

The following UK-based suppliers stock research-grade, lyophilised peptides for in-vitro and pre-clinical work. Purity and provenance vary; always request a Certificate of Analysis (CoA) and confirm cold-chain storage on arrival. None of the products linked below are approved for human use.

  • PeptideAuthority.co.uk

    UK-based research peptide supplier with batch certificates of analysis and >99% purity testing.

  • PeptideBarn.co.uk

    Wide catalogue of research-grade lyophilised peptides shipped from the UK, including bulk vials.